Jim M. Koeller, MS, FHOPA, discusses the inherent variability of recombinant DNA technology behind biosimilars.
Jim M. Koeller, MS FHOPA
Advertisement
Articles by Jim M. Koeller, MS FHOPA
Jim M. Koeller, MS FHOPA, discusses the heterogeneity of biologics.
Advertisement
Latest Updated Articles
The Heterogeneity of BiologicsPublished: November 12th 2019 | Updated:
Explaining the Variability of Biologics and BiosimilarsPublished: December 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5